Clinical Trials Logo

T-Cell Lymphoma clinical trials

View clinical trials related to T-Cell Lymphoma.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03628612 Enrolling by invitation - Multiple Myeloma Clinical Trials

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

Start date: August 3, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to monitor all patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

NCT ID: NCT03207789 Enrolling by invitation - T-cell Lymphoma Clinical Trials

T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients

Tcell-Brazil
Start date: January 1, 2015
Phase: N/A
Study type: Observational [Patient Registry]

The designed study follows up on the previous one by the international T-cell project (Bellei et al,, 2012) and its purpose is to verify whether a prospective collection of data would permit access to more accurate information permitting a better definition of prognosis and investigation of more adequate treatment strategies for these neoplasms. The analysis of patients distributed in all five macro regions of the country and a comparison among them will provide a real picture of the disease in Brazil, limiting the bias probably found in the previous projects.

NCT ID: NCT01854112 Enrolling by invitation - T-cell Lymphoma Clinical Trials

Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma

Start date: November 2012
Phase: N/A
Study type: Observational

Radiation therapy, total skin electron therapy (TSET), achieves a high response rate and is an effective treatment for cutaneous T-cell lymphoma affecting the superficial region 1. One the most widely used TSET techniques consists of six dual fields initially developed at Stanford University 2. Dosimetrically, TSET at energies of about 3-7 MeV at the surface of a standing patient may result in significant dose variations due to variable skin distance, self shielding, irradiated fields overlapping and patient motion. Deviations occur from the prescription dose up to 40% and the surface dose inhomogeneity as much as 90% in body areas such as the perineum and eyelid, are revealed in the literature. To improve this condition, a selection of patients with advanced skin disease and regional extension could be cured by a combination of TSEB and photon beam irradiation. Helical tomotherapy (HT) has advantages in irradiating extended volumes with treatment length of up to 160 cm, continuously in a helical pattern without the need for field junction. Total marrow irradiation (TMI) via HT with low toxicities for bone marrow transplantation of Asia multiple myeloma patients could be feasible . A study of HT for total scalp irradiation has also shown that the employment of directional and complete blocking on the inner structures can effectively force the tangential delivery of the majority of beamlets to the PTV, which can limit the treatment depth. Using HT, an image-guided intensity-modulated radiotherapy, to replace conventional TSI technique to increase dose delivery and decrease toxicities could be a workable and feasible. Here, we applied TSI via HT (HITS) for a woman with T cell lymphoma failure by chemotherapy, topic UV irradiation and local radiotherapy (RT) in MMH to overcome the surface dose inhomogeneity by conventional RT. Additionally, we will compare the advantages and disadvantages between the plan of HT and conventional RT for TSI.